Aimmune Therapeutics Announces Phase 2 Follow-On Study of AR101 for the Treatment of Peanut Allergy Demonstrated Increased Desensitization and Improved Tolerability with Low-Dose Maintenance by longitudeadmin | Mar 6, 2016 | Portfolio News
Aimmune Therapeutics Announces Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update by longitudeadmin | Mar 3, 2016 | Portfolio News
Commentary in The American Journal of Medicine Reinforces the Value of the Corus CAD Test in Evaluating Symptomatic Patients With Suspected Obstructive Coronary Artery Disease by longitudeadmin | Mar 2, 2016 | Portfolio News
Corcept Therapeutics Announces 2015 Financial Results by longitudeadmin | Mar 1, 2016 | Portfolio News
Esperion Therapeutics Provides Bempedoic Acid Development Program Update; Reports Fourth Quarter and Full Year 2015 Financial Results by longitudeadmin | Feb 25, 2016 | Portfolio News
